About Kennel Cough Treatment
Kennel cough is a highly infectious respiratory infection that triggers a prolonged honking cough in dogs. The disorder is usually self-limiting, with symptoms disappearing in two to three weeks. A sudden occurrence of a serious cough is common, which is usually ineffective but may become productive if pneumonia develops. The cough is usually a honking cough that can be brought about by massaging the throat. There may also be gagging, retching, sneezing, and nasal discharge. Exercise, enthusiasm, or pressure on the neck from the collar may all aggravate the cough. The trachea and bronchi of the lungs are damaged and irritated by these infectious agents, which attack the cells of the respiratory tract. Cough suppressants and antibiotics such as baytril, doxycycline, and others can be used to treat kennel cough.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Europe Players will contribute the maximum growth to Global Kennel Cough Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
DuchefaFarma B.V. (Netherlands), Ningbo distant chemicals (China), Zoetis Inc (United States), Boehringer Ingelheim Animal Health (France), Schering-Plough Animal Health Corporation (Indonesia), Elanco (United States), Bayer AG (Germany), CevaSanteAnimale S.A. (France), Virbac SA (France), Vetoquinol SA (France), IDEXX Laboratories, Inc. (United States) and Covetrus, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Alivira Animal Health Ltd. (India), Zovix Pharmaceuticals (India) and Others.
Segmentation Overview
AMA Research has segmented the market of Global Kennel Cough Treatment market by , Application (Mild Cases and Secondary Infection) and Region.
On the basis of geography, the market of Kennel Cough Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Baytril will boost the Kennel Cough Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Kennel Cough Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Veterinary Hospitals will boost the Kennel Cough Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Rising Adoption and Ownership of Dogs
Market Growth Drivers:
Increasing Prevalence of Infectious Disease and Rising Awareness about Dog Health
Challenges:
Manufactures have to comply with the Drug Regulations
Restraints:
Adverse Reaction of Some Drugs on Dogs
Opportunities:
Expansion of the Dog Healthcare Sector
Market Leaders and their expansionary development strategies
In June 2019, Veterinary equipment maker Midmark Corp. expanding its animal boarding and containment offerings through the acquisition of a competitor, Mason Company.
In September 2022, Merck Animal Health has announced the domestic launch of the first oral Bordetella bronchiseptica and canine parainfluenza virus vaccine with mucosal protection and easy oral administration. The Nobivac Intra-Trac Oral BbPi formulation is expected to become available for veterinary clinics to purchase in the United States in fall 2022, the company noted in an organizational release.
Key Target Audience
Manufacturers of Kennel Cough Drug, Suppliers of Kennel Cough Drug, Wholesalers, Distributors and Retailers of Kennel Cough Drug and Pharmaceutical Industry
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.